Kwon Yong-Dae, Jo Hyunmi, Kim Jae-Eun, Ohe Joo-Young
Department of Oral and Maxillofacial Surgery, School of Dentistry, Kyung Hee University, Seoul, South Korea.
Department of Oral and Maxillofacial Surgery, Kyung Hee University Medical Center, Seoul, South Korea.
Maxillofac Plast Reconstr Surg. 2023 Sep 14;45(1):31. doi: 10.1186/s40902-023-00398-2.
Risk factors for developing medication-related osteonecrosis of the jaw (MRONJ) include the general condition of the patient, smoking habit, poor oral hygiene, and the type, duration, and administration route of the drug, dentoalveolar surgery, such as implant placement. This study aimed to discuss whether implants may induce osteonecrosis in older patients receiving long-term medication and to analyze the radiological pattern of the bone necrosis.
This study included 33 patients diagnosed with dental implant-associated medication-related osteonecrosis of the jaw. Data regarding the medical history, type of medication used, durations of administration, laboratory test results, onset of bone necrosis since implant placement, type of opposing teeth, and radiological pattern of the bone necrosis on cone-beam computed tomography were recorded in patients with and without implants.
The most commonly used drug was bisphosphonate, with an average duration of use of 61.37 (± 53.72) months. The laboratory results showed average serum C-terminal cross-linking telopeptide (CTX) level of 0.23 ng/mL, vitamin D, 23.42 ng/mL, and osteocalcin, 4.92 ng/mL. Osteonecrosis occurred after an average of 51.03 (± 39.75) months following implant placement. Radiological evaluation revealed obvious sequestration in the implant-absent group, and the formation of a unit sequestration with an implant fixture (en bloc) was observed in the implant-present group. The patients underwent surgical treatment of sequestrectomy and explantation.
Implant placement, especially loading, may be considered a potential risk factor for the development of osteonecrosis in patients undergoing antiresorptive treatment.
发生药物性颌骨坏死(MRONJ)的风险因素包括患者的一般状况、吸烟习惯、口腔卫生差、药物的类型、持续时间和给药途径、牙槽外科手术,如种植体植入。本研究旨在探讨种植体是否会在接受长期药物治疗的老年患者中诱发骨坏死,并分析骨坏死的影像学表现。
本研究纳入了33例诊断为种植体相关药物性颌骨坏死的患者。记录有种植体和无种植体患者的病史、所用药物类型、给药持续时间、实验室检查结果、自种植体植入后骨坏死的发生情况、对颌牙类型以及锥形束计算机断层扫描上骨坏死的影像学表现。
最常用的药物是双膦酸盐,平均使用时间为61.37(±53.72)个月。实验室结果显示血清C端交联端肽(CTX)平均水平为0.23 ng/mL,维生素D为23.42 ng/mL,骨钙素为4.92 ng/mL。种植体植入后平均51.03(±39.75)个月发生骨坏死。影像学评估显示无种植体组有明显的死骨形成,有种植体组观察到种植体固定装置与死骨形成一个整体(整块)。患者接受了死骨切除术和种植体取出术的外科治疗。
种植体植入,尤其是负重种植,可能被认为是接受抗吸收治疗患者发生骨坏死的一个潜在风险因素。